14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Feb 06, 2026
AKRO vs GBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Feb 06, 2026, Akero Therapeutics, Inc. (AKRO) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas GBIO carries 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs GBIO. Trailing 12-month operating profitability (AKRO 0.0% vs GBIO -2020.0%) and valuation multiples (AKRO N/M vs GBIO 7.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $38.7M market capitalization and -2020.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ AKRO vs GBIO Key Questions & Quantitative Answers
As of Feb 06, 2026, Akero Therapeutics, Inc. (AKRO) is the stronger overall head-to-head candidate over Generation Bio Co. (GBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AKRO carries a Unified Composite Score of 60.0/100 (BUY) at $54.65 (N/M Forward P/E, 0.0% operating margin), whereas GBIO carries 58.8/100 (HOLD) at $5.34 (7.9x Forward P/E, -2020.0% operating margin). Technically, AKRO sits in a Markup phase (RSI 67.3, UNCLASSIFIED options structure) and GBIO sits in a Neutral phase (RSI 39.7, UNCLASSIFIED options structure).
AKRO leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with GBIO at -78.9% YoY revenue growth and +0.0% YoY earnings growth on $15M TTM revenue (N/A gross margin, -2020.0% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $15M for GBIO. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GBIO.
GBIO screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas GBIO trades at 7.9x Forward P/E, 7.9x Trailing P/E, N/M PEG, and 2.5x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus GBIO (-80.8% ROE) capital efficiency.
In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, GBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 26% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Feb 06, 2026. For educational research only; not investment advice.